Janux Therapeutics, Inc.

Clinical-stage oncology biotech developing tumor-activated T-cell engagers, led by JANX007 in metastatic castration-resistant prostate cancer.

Back to company catalog

Oncology / prostate cancer · Tumor-activated T-cell engager immunotherapies · Phase 1b

Compare report options